BG
LGND icon

Bellevue Group’s Ligand Pharmaceuticals LGND Stock Holding History

Bellevue Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-24,847
Closed -$1.62M – 222
2019
Q4 		$1.62M Buy
+24,847
New +$1.66M 0.03% 138
2019
Q1 		– Sell
-38,264
Closed -$3.24M – 144
2018
Q4 		$3.24M Buy
38,264
+20,198
+112% +$2.15M 0.21% 86
2018
Q3 		$3.09M Sell
18,066
-1,282
-7% -$193K 0.2% 93
2018
Q2 		$2.5M Sell
19,348
-7,342
-28% -$819K 0.21% 80
2018
Q1 		$2.75M Sell
26,690
-14,026
-34% -$1.39M 0.27% 65
2017
Q4 		$3.48M Sell
40,716
-37,350
-48% -$3.24M 0.36% 60
2017
Q3 		$6.63M Sell
78,066
-23,564
-23% -$1.87M 0.69% 47
2017
Q2 		$7.7M Sell
101,630
-88,390
-47% -$6.18M 0.91% 46
2017
Q1 		$12.5M Sell
190,020
-9,602
-5% -$632K 1.67% 19
2016
Q4 		$12.7M Buy
199,622
+28,293
+17% +$1.79M 2.59% 9
2016
Q3 		$10.9M Buy
171,329
+57,468
+50% +$4.22M 1.97% 12
2016
Q2 		$8.47M Sell
113,861
-17,312
-13% -$1.28M 1.59% 18
2016
Q1 		$8.76M Buy
+131,173
New +$7.97M 1.59% 18

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Bellevue Group's LGND Position: Q1 2020 in Review

Bellevue Group sold out of Ligand Pharmaceuticals (LGND) in Q1 2020, closing a stake of 24,847 shares — an estimated $1.62M sold.

Bellevue Group first reported a position in LGND in Q1 2016 and held it in 13 quarters. The position peaked at $12.7M in Q4 2016. 262 funds tracked by Wall St. Rank hold LGND as of Q1 2020.

  • Bellevue Group reported no remaining Ligand Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Bellevue Group sold 24,847 Ligand Pharmaceuticals shares in Q1 2020, an estimated $1.62M.
  • Bellevue Group first reported a position in Ligand Pharmaceuticals in Q1 2016 and held it in 13 quarters.
  • Bellevue Group's Ligand Pharmaceuticals position peaked at $12.7M in Q4 2016.
  • 262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2020.

Based on Bellevue Group's 13F filing for Q1 2020, filed 14 May 2020.